Vernon E Steele

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
  2. ncbi Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
  3. ncbi Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
  4. ncbi Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012
  5. ncbi Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
  6. ncbi Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Oncol Rep 25:1389-97. 2011
  7. ncbi Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
  8. ncbi Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
  9. ncbi 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:571-8. 2005
  10. ncbi Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, NIH, NCI, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Oncol Rep 26:731-6. 2011

Detail Information

Publications20

  1. ncbi Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
    ..These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis...
  2. ncbi Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
    ..Similarly, atorvastatin failed to alter the development of estrogen receptor-negative mammary carcinomas in a new animal model using bitransgenic mice (MMTV-Neu(+/-)/p53KO(+/-)), whereas bexarotene (250 mg/kg diet) was effective...
  3. ncbi Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
    ..We optimized agent testing in an in vivo bladder cancer model and determined the most sensitive, relevant protocol to test efficacy in clinical prevention trials...
  4. ncbi Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012
    ..There was minimal overlap of efficacy. That is, models which were relatively susceptible to NSAIDs or COX-2 inhibitors tended not to be sensitive to Targretin and vice versa...
  5. ncbi Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
    ..Thus, R115777 was active in the prevention and therapy of these chemically induced mammary cancers, but was strikingly more effective in cancers with HaRas mutations...
  6. ncbi Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Oncol Rep 25:1389-97. 2011
    ..In particular, cell cycle genes related to the anaphase protein complex (APC) pathway, including CDC 20, cyclin B1, BUB1 and both of the Aurora kinases, were significantly decreased...
  7. ncbi Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
    ..Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels...
  8. ncbi Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
    ..Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone...
  9. ncbi 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:571-8. 2005
    ..The anti-apoptotic protein survivin was not expressed in normal bladder epithelium, but was variably expressed in cancers. FHIT and survivin expressions were similar in cancers from indomethacin-treated and non-treated mice...
  10. ncbi Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, NIH, NCI, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Oncol Rep 26:731-6. 2011
    ..In contrast, DIM had minimal effects in either model; arguing that administration of DIM is not analogous to administration of I3C...
  11. ncbi Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 6:2022-8. 2007
    ..The bioavailability of these tea polyphenols to different organ sites may contribute to the differing preventive efficacy of Polyphenon E against urinary bladder and mammary cancers...
  12. ncbi Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 123:2254-9. 2008
    ..In summary, rosiglitazone over a wide dose range enhanced urinary bladder carcinogenesis in the OH-BBN model in rats...
  13. ncbi Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Res 62:6506-9. 2002
    ..The above correlations may be of predictive value in the search for new chemoprotective agents. The overall molecular mechanism of the inhibition of ACF by the 3-nitroflavones under study appears to involve redox reactions...
  14. ncbi The use of animal models for cancer chemoprevention drug development
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    Semin Oncol 37:327-38. 2010
    ..Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process...
  15. ncbi Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells
    Vernon E Steele
    Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:3205-15. 2006
    ..Because DHEA can be converted to androgens or estrogens, such use may promote prostate cancer. In this study, the effects of DHEA were compared with those of DHT using gene expression array profiles in human LNCaP prostate cancer cells...
  16. ncbi Is inducible nitric oxide synthase a target for chemoprevention?
    James A Crowell
    National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, Bethesda, Maryland 20892, USA
    Mol Cancer Ther 2:815-23. 2003
    ....
  17. ncbi Current mechanistic approaches to the chemoprevention of cancer
    Vernon E Steele
    Chemoprevention Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biochem Mol Biol 36:78-81. 2003
    ..Thus, agent combination prevention strategies are essential to decrease cancer morbidity. Furthermore, each cancer type may require custom combination of prevention strategies to be successful...
  18. ncbi Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
    ..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality...
  19. ncbi Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
    ..Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful...
  20. ncbi Targeting the AKT protein kinase for cancer chemoprevention
    James A Crowell
    Division of Cancer Prevention, National Cancer Institute, NIH, Executive Plaza North, Room 2117, 900 Rockville Pike, Bethesda, MD 20892, USA
    Mol Cancer Ther 6:2139-48. 2007
    ....